Stoke Therapeutics (0GT) Stock Overview

Engages in the development of treatments for severe genetic diseases by upregulating protein expression. More details

0GT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 90.9% below our estimate of its fair value

Revenue is forecast to grow 56.28% per year

Risk Analysis

Significant insider selling over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

0GT Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Stoke Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Stoke Therapeutics
Historical stock prices
Current Share Price	US$24.80
52 Week High	US$32.80
52 Week Low	US$9.50
Beta	1.19
1 Month Change	-2.21%
3 Month Change	-7.46%
1 Year Change	148.00%
3 Year Change	100.00%
5 Year Change	-17.88%
Change since IPO	2.39%

Recent updates

Shareholder Returns

	0GT	DE Biotechs	DE Market
7D	-3.0%	-1.2%	2.4%
1Y	148.0%	-5.6%	3.9%

Return vs Industry: 0GT exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 0GT exceeded the German Market which returned 3.3% over the past year.

Price Volatility

Is 0GT's price volatile compared to industry and market?
0GT volatility
0GT Average Weekly Movement	6.6%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.9%
10% most volatile stocks in DE Market	13.2%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: 0GT has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 0GT's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	170	Ian Smith	www.stoketherapeutics.com

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials.

Stoke Therapeutics, Inc. Fundamentals Summary

How do Stoke Therapeutics's earnings and revenue compare to its market cap?
0GT fundamental statistics
Market cap	€1.58b
Earnings (TTM)	-€147.71m
Revenue (TTM)	€27.91m

58.7x

P/S Ratio

-11.1x

P/E Ratio

Is 0GT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0GT income statement (TTM)
Revenue	US$32.08m
Cost of Revenue	US$0
Gross Profit	US$32.08m
Other Expenses	US$201.85m
Earnings	-US$169.77m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.73
Gross Margin	100.00%
Net Profit Margin	-529.20%
Debt/Equity Ratio	0%

How did 0GT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/17 16:28
End of Day Share Price	2026/06/17 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Stoke Therapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gregory Harrison	BofA Global Research
Thomas Shrader	BTIG
Michelle Gilson	Canaccord Genuity

Stoke Therapeutics (0GT) Stock Overview

Rewards

Risk Analysis

Stoke Therapeutics, Inc. Competitors

Biotest

Biotest GmbH KGaA

2invest

Formycon

Price History & Performance

Recent News & Updates

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2026

Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Stoke Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of STK-002

Stoke Therapeutics, Inc. Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Recent updates

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2026

Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Stoke Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of STK-002

Stoke Therapeutics, Inc. Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome

Stoke Therapeutics, Inc. Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2025

Stoke Therapeutics, Inc. Announces CEO Changes, Effective March 19, 2025

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate A Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc. Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.55 loss in 3Q 2023)

Stoke Therapeutics, Inc. Appoints Eric Olson as Chief Business Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.46 loss per share (vs US$0.69 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2023)

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000004 million.

Stoke Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: US$2.38 loss per share (vs US$2.60 loss in FY 2022)

New major risk - Share price stability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.66 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.63 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome

Insufficient new directors

Stoke Therapeutics, Inc. Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

High number of new directors

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Growth Index

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and Opa1 Protein Upregulation in Retinal Tissue Following Administration of Stk-002

High number of new directors

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

New 90-day high: €52.50

New 90-day high: €46.00

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer

New 90-day high: €34.20

New 90-day high: €32.20

Stoke Therapeutics, Inc. Announces Plans to Move Forward with Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a Monarch Study for Dravet Syndrome

Shareholder Returns

Price Volatility

About the Company

Stoke Therapeutics, Inc. Fundamentals Summary